DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTICTARGET
Andrea Ghelli Luserna di Rorà(Fondazione Pisa), G. Martinelli, Robustelli, Anna Ferrari(University of Bologna), Mc Abbenante, Chiara Sartor(University of Bologna), Alessandro Vitale(University of Padua), Emanuela Ottaviani(University of Bologna), Sonia Ronconi(Istituti di Ricovero e Cura a Carattere Scientifico), Annalisa Lonetti(University of Bologna), Domenico Russo, C. Venturi, Silvia Carloni, Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Margherita Perricone(University of Bologna), Ilaria Iacobucci(St. Jude Children's Research Hospital), Guadagnuolo, Federica Cattina(University of Brescia), Enrica Imbrogno(University of Bologna), Gerardo Musuraca(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), L Elia, Enrico Derenzini(University of Milan)
Unknown
January 1, 2013
Cited by 0
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
The genomic landscape of pediatric acute lymphoblastic leukemia
|Nature Genetics|2022|412